Research from EqualOcean, EqualOcean

EqualOcean

Research from EqualOcean

EqualOcean is an investment research firm and information service provider focusing on China's Technology, Automotive and Consumer Internet sectors. With unique research and due diligence methodology, we provide tailored insights into a wide range of industries and companies, empowering our clients' value-added decisions.

Founded in 2014, EqualOcean is headquartered in Beijing and has offices in Shanghai, Shenzhen and New York.

Thematic (Sector/Industry)

<ul><li>GT (Cell and Gene Therapy) is a sector with high growth potential.</li><li>CAR-T, as one of the main CGT currently, presents great value for both doctors and patients.</li><li>This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.</li></ul>

GT (Cell and Gene Therapy) is a sector with high growth potential.CAR-T, as one of the main CGT currently, presents great value for both doctors and patients.This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

Opportunities and Challenges Hidden in the CGT Industry in China

United States

Gracell Biotechnologies Inc. operates as a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing cell therapies to address medical needs in the treatment of cancer. Gracell Biotechnologies aims to disrupt conventional approaches to CAR-T cell therapies with technology platforms-FasTCAR and TruUCAR.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gracell Biotechnologies Inc (GRCL US)

Opportunities and Challenges Hidden in the CGT Industry in China

GT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors...

EqualOcean

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)